- Tags: retina
Research
Advanced AMD linked to imbalanced gut microbiome
Though seemingly unrelated, gut flora may play a surprising role in the pathogenesis of age-related macular degeneration (AMD).
Research
Myopia may delay DR development and progression
Study used Mendelian randomization to identify a causal relationship between myopia and diabetic retinopathy.
Research
Women with osteoporosis more prone to AMD development
Study highlights the key role of declining estrogen levels in the risk of developing AMD and osteoporosis.
Products
Regeneron receives FDA CRL, delaying Eylea HD sBLA approval
Company plans to resubmit app for pre-filled syringe version in early 2026, noting two 2025 dates to watch for.
Pipeline
Nanoscope reports 3-year vision improvements for RP optogenetic therapy
Long-term extension from phase 2b/3 RESTORE trial notes potential of MCO-010 as a one-time, gene-agnostic optogenetic therapy.
Business
Lilly to purchase Adverum Biotechnologies
With a Q4 closing date in mind, acquisition supports ongoing clinical trials and development activities for Ixo-vec, a one-time IVT gene therapy injection to treat wet AMD.
Research
Atopic dermatitis linked to increased risk for AMD
Study highlights importance of monitoring adult patients with atopic dermatitis for signs of AMD.
Business
EssilorLuxottica purchases RetinAI
Ikarian subsidiary is the developer of the FDA-cleared Discovery platform, an AI-based imaging data management system for diagnosing and monitoring ophthalmic disease progression.
Pipeline
Complement Therapeutics' GA gene therapy IND receives FDA clearance
Clearance gives green light to begin Q1 2026 patient enrollment for the Opti-GAIN study evaluating CTx001 as a one-time, durable treatment.
Business
Topcon purchases Toku, Inc
Acquisition supports ongoing Healthcare from the Eye initiative with a portfolio of AI-based diagnostic and retinal imaging technology.
Research
Lower AMD risk tied to long-term metformin use
Study joins growing body of research on the protective effect of metformin against AMD risk in diabetic patients.
Pipeline
Nanoscope's optogenetic therapy demonstrates visual improvements for Stargardt
Findings from phase 2 STARLIGHT trial support the safety and efficacy of MCO-010 in Stargardt disease.
Products
Optos unveils advanced Silverstone RGB UWF imaging system
Debuting at AAO, the ultra-widefield imaging platform delivers nine imaging modalities—the broadest spectrum of retinal imaging capabilities available for clinicians.
Products
FDA approves Celltrion's Eylea bisoimilar
EYDENZELT (aflibercept-bvoa) is indicated for patients with wet AMD, macular edema following RVO, DME, and DR.
Pipeline
FDA grants Orphan Drug designation to AAVantgarde's Stargardt gene therapy
Regulatory milestone is second designation for AAVB-039; includes tax credits for qualified clinical testing and, if approved, seven years of U.S. market exclusivity.
Pipeline
FDA grants Breakthrough Therapy Designation to Nacuity's RP tablets
Third designation for NPI-001 follows recent positive 24-month data showing a 50% photoreceptor reduction after 2 years of daily dosing.
Products
CMS assigns permanent J-code for Neurotech's ENCELTO cell therapy
The allogeneic encapsulated cell-based therapy is the first and only treatment approved by the FDA for the treatment of MacTel.
Research
Could the retina help detect early hearing loss?
Study highlights utility of retinal microvascular parameters to detect early signs of hearing loss.
Business
Ollin Biosciences debuts with next-gen ophthalmic pipeline
Biotech launches with $100 million financing and a lead program addressing wet AMD and DME via a higher potency VEGF/Ang2 bispecific antibody.
Pipeline